Arbutus Biopharma Corporation (ABUS) Social Stream
ARBUTUS BIOPHARMA CORP (ABUS) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering ARBUTUS BIOPHARMA CORP.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-08 | 5 | $9 | $4 | $6 | $2.5 | 140% |
| 2021-12-02 | 5 | $9 | $4 | $6.625 | $2.5 | 165% |
| 2021-12-29 | 5 | $9 | $4 | $6.1 | $2.5 | 144% |
| 2022-02-02 | 5 | $9 | $4 | $6.3 | $2.5 | 152% |
| 2022-03-07 | 4 | $9 | $5 | $7 | $2.5 | 180% |
| 2022-05-09 | 4 | $9 | $5 | $7.125 | $2.5 | 185% |
| 2022-08-06 | 4 | $9 | $5 | $6.875 | $2.5 | 175% |
| 2022-11-10 | 3 | $6 | $5 | $5.666 | $2.5 | 126.64% |
| 2023-03-05 | 4 | $6 | $5 | $5.666 | $2.5 | 126.64% |
| 2023-05-05 | 3 | $6 | $5 | $5.75 | $2.5 | 130% |
| 2023-08-04 | 4 | $6 | $5 | $5.75 | $2.5 | 130% |
| 2023-11-08 | 4 | $6 | $4 | $5.25 | $2.5 | 110% |
The Trend in the Analyst Price Target
Over the past 33 months, ABUS's average price target has gone down $1.75.
Over the past 36 weeks, ABUS's average upside potential has been 129.01%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-05-05 | 4 | 6 | 5 | 5.75 | 2.60 | 121.15% |
| 2023-05-05 | 3 | 6 | 5 | 5.75 | 2.60 | 121.15% |
| 2023-08-04 | 4 | 6 | 5 | 5.75 | 2.14 | 168.69% |
| 2023-09-12 | 4 | 6 | 4 | 5.25 | 2.03 | 158.62% |
| 2023-11-08 | 4 | 6 | 4 | 5.25 | 1.87 | 180.75% |
ABUS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 4 | 0 | 0 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
ABUS's average broker recommendation rating improved by 1 over the prior 45 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- ARBUTUS BIOPHARMA CORP's average analyst price target is higher than 73.37% of all US stocks.
- ABUS has a higher number of analysts covering the stock than 189.48% of all US stocks.
- In the context of Pharmaceutical Products stocks, ARBUTUS BIOPHARMA CORP's variance in analysts' estimates is lower than -327.14% of them.
- ARBUTUS BIOPHARMA CORP's upside potential (average analyst target price relative to current price) is higher than 815.42% of stocks in the small market cap category.
Stocks similar to ARBUTUS BIOPHARMA CORP in the Pharmaceutical Products industry regarding analyst recommendations and price targets are LPCN, RGLS, and ATOS.
View All Top Stocks by Price Target
What is the outlook for ABUS? Use POWR Ratings for clearer insight into price direction.